RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $270 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an 'Outperform' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $270.
October 06, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an 'Outperform' rating on Alnylam Pharmaceuticals and maintained a price target of $270.
The reiteration of an 'Outperform' rating by RBC Capital indicates a positive outlook for Alnylam Pharmaceuticals. The maintained price target of $270 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100